The risk of dyslipidemia and other metabolic disorders such as obesity and diabetes mellitus has been shown to be 1.5 to 2 times greater in patients treated with atypical antipsychotics than in patients in the general population.18 Dyslipidemia associated with insulin resistance includes hypertriglyceridemia, an increase in very low-density lipoprotein (VLDL) secretion from the liver, an increase